well you get a one minute assessment.
bmks270 said:
Great insight, that's why this thread exists.
Champ - be very careful about your entry price here. I don't know the specifics of this potential merger, but empirical evidence shows that the acquirer's stock suffers in the short term, while the target's price increases (as there's usually a premium paid over pre-announcement target stock price). The two exceptions I can think of are if the deal is immediately accretive to the acquirer's EPS, or if there is widespread enthusiasm about synergies resulting from the combination. Both of these situations are RARE!Champ Bailey said:
Rocky is down about 5% over the last week, and they are apparently in final negotiations with acquiring Quibi. Seems like a good opportunity to get in some more.
Doesn't seem like a good outcome considering the value proposition. Will stay away from those places in the future.bmks270 said:third coast.. said:
Telemedicine is how all these quack hairloss and ed places you see commercials for make all their money.
Is it? Is your thesis they don't have lasting power? How should we take that into consideration?
I bleed maroon said:Champ - be very careful about your entry price here. I don't know the specifics of this potential merger, but empirical evidence shows that the acquirer's stock suffers in the short term, while the target's price increases (as there's usually a premium paid over pre-announcement target stock price). The two exceptions I can think of are if the deal is immediately accretive to the acquirer's EPS, or if there is widespread enthusiasm about synergies resulting from the combination. Both of these situations are RARE!Champ Bailey said:
Rocky is down about 5% over the last week, and they are apparently in final negotiations with acquiring Quibi. Seems like a good opportunity to get in some more.
Do a bit of research on the impact of acquisitions on share prices - history would tell you to wait for an inevitable near-term pullback in the shares of the acquirer before accumulating.
Of course, your mileage may vary - happy investing!
$30,000 Millionaire said:
$TDOC looks poised for a move to $250. Am I wrong?
Champ Bailey said:
You mind describing exactly what the move is?
TxAG#2011 said:Champ Bailey said:
You mind describing exactly what the move is?
Number go up a lot
As far as antitrust, I don't even see that being a big risk. AMZN is the 800 lb. gorilla in two spaces, at least (AWS and eCommerce), and even if the drastic step of a breakup occurs, I think shareholder value would still be preserved (it might even be more valuable as separate companies?).TxAG#2011 said:
Disagree. Amazon's biggest threat is antitrust and now that they've demonstrated to be a weapon for the dems I don't think they will go after them.
bmks270 said:
Here are some more ideas for long term holds:
GOOG.... looking at the revenue growth and PE I think GOOG may be undervalued relative to MSFT and AAPL. Just seems like the stock price has lagged tech sector growth. Maybe there is some reason investors are avoiding it (fear of being broken up?). But the revenue growth looks stable.
LLY.... Eli Lily... my friend in the healthcare industry turned me on to this one. They make diabetes testers and insulin. Well, diabetes isn't going away. I think this has potential to continue to be a consistent growth stock. It's performed well over the past few years and in 2020.
TDOC... Teladoc. An obvious choice. The tele-medicine is here to stay. Revenue growth has been huge for Teledoc. I think the trend will continue. The one pitfall is this company still hasn't turned a profit, but it's business has been exploding. The shift to tele-medicine is permanent. Another consideration is a few competitors have entered the space, so there is risk Teledoc gets pushed aside by ZOOM or even the insurances companies rolling out their own tele-medicine platforms.
Other attractive market leaders with stable revenue and growth models are ROKU, NFLX, and ADBE.
As always, do your own research on the income and business models of these companies, but I think all of them are likely to have very stable revenue growth going forward.
Thanks for the news! Good news - I have positions in both of these! Bad news - my ROKU position is long put options.bmks270 said:
Two stocks mentioned on Jan. 2 above with big moves:
ROKU up about 18% since Wednesday on new streaming and user numbers.
Eli Lilly (LLY) popped 11% today on trials of Alzheimer's treatment.
https://www.cnbc.com/2021/01/11/eli-lilly-says-its-alzheimers-drug-slows-clinical-decline-in-mid-stage-trial.html
bmks270 said:
Other attractive market leaders with stable revenue and growth models are ROKU, NFLX, and ADBE.
As always, do your own research on the income and business models of these companies, but I think all of them are likely to have very stable revenue growth going forward.
I'm personally not a fan of holding leveraged ETFs long term due to the decay that eventually occurs.tarletontexan said:
Still going with a strategy in my growth account of holding TQQQ long. I expect less top end growth with a Biden administration, but I also see more global stability. Within a 3x daily nasdaq etf that should lead to more sizable gains just due to